Sunday, October 21, 2012

Lyrica Patent Expiration

Lyrica, a drug for epilepsy and diabetic peripheral neuropathy, is Pfizer's second best-selling drug with $3.7B in sales in 2011. Pfizer's annual report stated that generic competition may impact Lyrica's sales; on the other hand, Pfizer has filed an NDA for Lyrica to treating neuropathic pain due to spinal cord injuries. As a result, Lyrica's sales may actually be able to continue to grow. It is anticipated that Pfizer will reactivate its coupon program for Lyrica, providing copay assistance to combat the competition from generics.  See
Check out the deals and discounts we've found at BestFreeStuffGuide

Posted via email from susan's posterous

No comments:

Post a Comment